Inspections: Switzerland changes Conditions
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Federal Assembly has revised Art. 64a of the Therapeutic Products Act which regulates cross-border inspections. This refers both to inspections by foreign authorities in Switzerland and inspections by the Swiss authority abroad.
What does this mean?
- An inspection by a foreign authority is possible if the company agrees with the inspection (approval by the Swiss State Secretariat for Economic Affairs, SECO, is no longer required for that). This requires direct contact between the Swiss company to be inspected and the foreign authority as a consequence.
- Swissmedic must be informed in advance that an inspection is planned by a foreign inspectorate. The company will be informed in time by Swissmedic in case the inspection will be accompanied.
- After the inspection, the inspection report should be made available to Swissmedic.
The new approach will be effective as of 1 January 2018. The leaflet "General procedure for foreign governmental inspections in Switzerland related to therapeutic products" will be adjusted accordingly by the end of 2017.
Related GMP News
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight
19.01.2026GMP Auditor Association Developments September through December 2025
03.12.2025What are GMP Audits and what Qualifications do GMP Auditors need to have?
19.11.2025Root Cause Analysis and CAPA - Why FDA Keeps Calling Them Out
22.10.2025EMA Questions & Answers on Mutual Recognition Agreement (MRA) with US updated